Active not recruiting

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

I5B-MC-JGDP - ClinicalTrials.gov - NCT03086369

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Email
Active not recruiting

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

I5B-MC-JGDP - ClinicalTrials.gov - NCT03086369

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have metastatic (Stage 4) pancreatic cancer diagnosis

Participant must have tumor tissue available or be willing to provide a biopsy

Participant must have discontinued all previous treatments for cancer at least 4 weeks prior

Participant must have a life expectancy of at least 3 months

Participants must NOT

Participant must not have had first line treatment for metastatic pancreatic cancer

Participant must not have participated in another clinical trial within the last 30 days - Female participant must not have a positive pregnancy test or be lactating

Trial Summary

Conditions the trial is for

Pancreatic Cancer

What the trial is testing?

Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo

Could I receive a Placebo?

yes

Enrollment Goal

186

Trial Dates

June 2017 - January 2022

Trial Phase

1

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have metastatic (Stage 4) pancreatic cancer diagnosis

Participant must have tumor tissue available or be willing to provide a biopsy

Participant must have discontinued all previous treatments for cancer at least 4 weeks prior

Participant must have a life expectancy of at least 3 months

Participants must NOT

Participant must not have had first line treatment for metastatic pancreatic cancer

Participant must not have participated in another clinical trial within the last 30 days - Female participant must not have a positive pregnancy test or be lactating

Trial Summary

Conditions the trial is for

Pancreatic Cancer

What the trial is testing?

Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo

Could I receive a Placebo?

yes

Enrollment Goal

186

Trial Dates

June 2017 - January 2022

Trial Phase

1

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Pancreatic Cancer Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?